Litcius/Paper detail

Teclistamab, a B-cell maturation antigen × CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicentre, open-label, single-arm, phase 1 study

Saad Z. Usmani, Alfred L. Garfall, Niels W.C.J. van de Donk, Hareth Nahi, Jesús F. San Miguel, Albert Oriol, Laura Rosiñol, Ajai Chari, Manisha Bhutani, Lionel Karlin, Lotfi Benboubker, Lixia Pei, Raluca Verona, Suzette Girgis, Tara Stephenson, Yusri Elsayed, Jeffrey R. Infante, Jenna D. Goldberg, Arnob Banerjee, María‐Victoria Mateos, Amrita Krishnan

2021The Lancet313 citationsDOI

Topics & Concepts

Open labelMedicineMultiple myelomaBispecific antibodyAntibodyAntigenRefractory (planetary science)CD3OncologyImmunologyInternal medicineMonoclonal antibodyCD8Clinical trialBiologyAstrobiologyMultiple Myeloma Research and TreatmentsCAR-T cell therapy researchMonoclonal and Polyclonal Antibodies Research